Rifaximin Versus No Intervention for the Treatment of IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
Key facts
- Who runs it
- Fred Hutchinson Cancer Center
- Where
- Seattle, United StatesSee the site
- Trial code
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 50 people, planned
- Started
- 22 Jan 2026
- Expected to end
- 1 May 2028
- Type of study
- Interventional, 2 groups
- Treatments tested
- Rifaximin
- Biospecimen Collection
- Record updated
- 17 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- Age ≥ 18 years
- Ability to understand and willingness to sign a written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of potential study participants
- Clinical diagnosis of IgG/IgA (non-IgM) monoclonal gammopathy of undetermined significance (MGUS) based on International Myeloma Working Group (IMWG)-2014 criteria (Rajkumar et al, Lancet Oncology, 2014). It is recognized that not all patients with clinical diagnosis of MGUS undergo bone marrow biopsy. Bone marrow biopsy confirmation will not be required if not clinically indicated per treating provider
- Agree to use adequate contraception; For women of child-bearing potential: prior to study entry and for the duration of study participation; For men: prior to study entry, for the duration of study participation, and one month after completion of rifaximin administration (for men)
- No antibiotic use in the preceding 2 weeks
Who cannot take part
- Participants who are receiving other investigational agents
- Another concurrent malignancy requiring active therapy
- Known hypersensitivity to rifaximin
- Pregnant women
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
This trial is currently available in United States.
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, United StatesContact: Madhav Dhodapkar, MBBSTaking people
About the trial
What the trial wants to find out
This phase II trial compares the effect of rifaximin to no intervention for the treatment of IgG/IgA monoclonal gammopathy of undetermined significance (MGUS). Rifaximin is a type of antibiotic that is only used in cancer chemotherapy (antineoplastic antibiotic). It works by damaging the cell's DNA and may kill cancer cells or precancerous cells like those found with MGUS. Giving rifaximin may kill more precancerous cells in patients with IgG/IgA MGUS.
The 2 groups in the trial
- Arm A (Rifaximin)Treatment being tested
Patients receive rifaximin orally (PO) three times daily (TID) for 14 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood sample collection throughout the study.
Treatment: Rifaximin and Biospecimen Collection
- Arm B (No intervention)Other group
Patients undergo blood sample collection throughout the study.
Treatment: Biospecimen Collection
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Rifaximin Versus No Intervention in Patients With IgG/IgA (Non-IgM) Monoclonal Gammopathy of Undetermined Significance
- Criteria questions
- Built from NCT07209371, who can take part
- Record updated
- 17 August 2026